Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-042772
Filing Date
2025-02-28
Accepted
2025-02-28 17:03:31
Documents
7
Effectiveness Date
2025-02-28

Document Format Files

Seq Description Document Type Size
1 S-8 d892172ds8.htm S-8 29164
2 EX-5.1 d892172dex51.htm EX-5.1 5233
3 EX-23.1 d892172dex231.htm EX-23.1 1396
4 EX-FILING FEES d892172dexfilingfees.htm EX-FILING FEES 19040
5 GRAPHIC g892172dsp6c.jpg GRAPHIC 6059
6 GRAPHIC g892172g15i76.jpg GRAPHIC 8669
7 GRAPHIC g892172g94i30.jpg GRAPHIC 5051
  Complete submission text file 0001193125-25-042772.txt   83772
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285460 | Film No.: 25691910
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)